Laser and Light-Sensitive drug aim to zap prostate cancer without surgery
NCT ID NCT06807359
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new treatment for men with localized prostate cancer. It uses a light-sensitive drug called verteporfin, which is injected into the bloodstream and then activated by laser light delivered through thin fibers placed into the prostate. The goal is to destroy cancer cells while minimizing damage to healthy tissue. The study will enroll 43 participants and follow them for up to 3 years to check safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
verteporfin (a light-activated drug)
What this could lead to
If successful, this could offer a less invasive treatment option for localized prostate cancer that targets tumors precisely and reduces side effects compared to surgery or radiation.
What could go wrong
This is an early-phase trial with only 43 participants, so results may not apply to all patients. The treatment requires general anesthesia and carries risks like damage to nearby tissues or side effects from the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Klinik für Urologie, Universitätsklinikum Köln
RECRUITINGCologne, 50937, Germany
Contact
-
Klinik und Poliklinik für Urologie, Universitätsmedizin Rostock
RECRUITINGRostock, Germany
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact